Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07525817) titled 'A Real-World Study of Pirtobrutinib in cBTKi-Resistant/Intolerant Mature B-Cell Lymphoma' on April 1.

Study Type: Observational

Primary Sponsor: Ou Bai, MD/PHD

Condition: Mature B-Cell Lymphoma

Intervention: Drug: Pirtobrutinib

Recruitment Status: Not recruiting

Date of First Enrollment: April 1, 2026

Target Sample Size: 40

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07525817

Published by HT Digital Content Services with permission from Health Daily Digest....